CONNECT WITH AN ALNYLAM EDUCATOR
GraceChild with PH1*

*Alnylam is proud to feature real patients in our advertising. Patients may or may not be on an Alnylam therapy.

Contact an Alnylam Patient Education Liaison (PEL)

Our PELs have backgrounds in nursing. They can help educate patients and families about primary hyperoxaluria type 1 (PH1) and provide information about treatment with OXLUMO® (lumasiran). They can also connect you to more resources and answer questions.

Image

 

Alnylam Patient Education Liaisons: Patient Education Liaisons (PELs) are professionals with backgrounds in nursing who are experienced in educating patients and their families. PELs support patients and their families in a number of ways:

  • Engaging patients and families with educational resources
  • Answering questions about PH1 and treatment
  • Providing customized education, including one-on-one education or family meetings

The purpose of Alnylam Patient Education Liaisons (PELs) is to provide education to patients, their families, and caregivers. PELs are employees of Alnylam Pharmaceuticals and do not provide medical advice. All diagnosis and treatment decisions should be made by the treating physician and their patients.

Register today to have a PEL reach out to you to discuss questions you may have about PH1 and/or treatment with OXLUMO. Registration is quick and easy. Simply fill out the form below.

All fields required unless otherwise noted.

*Please enter your first name
*Please enter your last name
*Please enter your street address
*Please enter your city
*Please select your state
*Please enter your ZIP / postal code
*Please enter your phone number

OK to leave voicemail. (Optional)

I would like an Alnylam Patient Education Liaison to contact me with information about PH1.

I understand that the Alnylam PEL is not providing me medical advice and is not part of my healthcare team.

I understand that Alnylam will use reasonable technical and organizational measures to protect the information I share with the PEL and will not use or disclose it outside of the company.

By submitting this form, I agree to the Alnylam Privacy Policy. I am 18 years or older, a US resident, and consent to the processing of my personal data per the terms outlined in the Data Privacy Notification and Consent.

I would like to receive updates from Alnylam Pharmaceuticals regarding marketing communications, customer surveys, or for market research surveys.

IMPORTANT SAFETY INFORMATION

The most common side effect of OXLUMO® (lumasiran) is injection site reaction (redness, swelling, pain, bruising, itching, and discoloration at the site of injection). These are not all the possible side effects of OXLUMO. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1‑800‑FDA‑1088.

OXLUMO has not been studied in pregnant or breastfeeding women. Talk to your doctor about the risk of taking OXLUMO if you are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed.

WHAT IS OXLUMO?

OXLUMO is a prescription medicine for the treatment of primary hyperoxaluria type 1 (PH1) to lower oxalate in urine and blood in children and adults.  

For additional information about OXLUMO, please see full Prescribing Information.